Newsfeeds Archive - Page 471 of 19074

1 minute read

Citi Trends Appointed Ken Seipel As Interim CEO; David Makuen Steps Down As CEO And Board Member; Board Commences A Search Process For A Permanent CEO

May 31, 8:33 AM

Citi Trends, Inc. (NASDAQ:CTRN) ("Citi Trends" or the "Company"), a leading specialty value retailer of apparel, accessories and home trends for way less spend primarily for African American and multicultural families in

CTRN

2 minute read

Surging ‘Re-Staking’ Craze Draws $18B In Crypto Assets As Investors Seek Higher Returns

By Benzinga Neuro

May 31, 8:28 AM

More than $18 billion in cryptocurrency has flowed into new “re-staking” platforms, attracting investors with the promise of higher yields.

$ADA

2 minute read

How To Earn $500 A Month From Pfizer Stock

By Avi Kapoor

May 31, 8:23 AM

New York-based Pfizer currently has a dividend yield of 5.96% — a quarterly dividend of 42 cents a share ($1.68 a year).

PFE

2 minute read

OpenAI’s Apple Deal Sparks Concerns In Microsoft, Could Shift AI Market Dynamics

By Anusuya Lahiri

May 31, 8:22 AM

Microsoft concerned about potential Apple-OpenAI deal as it could impact its own AI ambitions. Altman aims to replace Google as Apple's search partner.

AAPL

2 minute read

Apple Set To Announce New AI Features At WWDC, But You Might Need At Least This iPhone To Use Them, Says Report

By Rounak Jain

May 31, 8:21 AM

Apple is set to unveil its AI strategy with Siri in focus, but users might need the latest top-tier iPhone 15 models to access all these features.

AAPL

1 minute read

Novartis Scemblix Phase III Data Shows Superior Efficacy With A Favorable Safety And Tolerability Profile Vs. Standard-Of-Care TKIs In Adults With Newly Diagnosed CML

By Benzinga Newsdesk

May 31, 8:20 AM

https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and-tolerability-profile-vs-standard-care-tkis-adults-newly-diagnosed-cml Phase

NVS

1 minute read

Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024

By Benzinga Newsdesk

May 31, 8:16 AM

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract

GILD

1 minute read

Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO

By Benzinga Newsdesk

May 31, 8:11 AM

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant

AUTL

1 minute read

Aptose Announces $4.43M Registered Direct Offering Of 3.855M Shares Of Common Stock At A Price Of $1.15/Share, Priced At-the-Market Under Nasdaq Rules

By Benzinga Newsdesk

May 31, 8:09 AM

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today

APTO

1 minute read

Haoxi Health Technology 2H 2023 EPS $0.03 Vs $0.02 YoY; Revenue $23.5M Vs $9.16M YoY

By Benzinga Newsdesk

May 31, 8:06 AM

Financial Highlights for the Six Months Ended December 31, 2023Total revenue for the six months ended December 31, 2023 was US$23.50 million, increased by US$14.34 million, or 157%, from US$9.16 million for the same

HAO